HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
-4.54%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$260M
AUM Growth
+$260M
(-3.5%)
Cap. Flow
+$7.99M
Cap. Flow
% of AUM
3.08%
Top 10 Holdings %
Top 10 Hldgs %
25.84%
Holding
172
New
35
Increased
39
Reduced
27
Closed
24
Top Buys
| 1 |
Quanta Services
PWR
|
$2.06M |
| 2 |
Bausch Health
BHC
|
$2.03M |
| 3 |
Mastercard
MA
|
$2.03M |
| 4 |
3M
MMM
|
$1.98M |
| 5 |
MasTec
MTZ
|
$1.9M |
Top Sells
| 1 |
HCP
HashiCorp, Inc. Class A Common Stock
HCP
|
$4.45M |
| 2 |
Amazon
AMZN
|
$2.95M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$2.23M |
| 4 |
Live Nation Entertainment
LYV
|
$2.02M |
| 5 |
Indivior
INDV
|
$1.83M |
Sector Composition
| 1 | Healthcare | 39.15% |
| 2 | Technology | 17.75% |
| 3 | Industrials | 8.61% |
| 4 | Consumer Discretionary | 6.17% |
| 5 | Financials | 5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Roivant Sciences
ROIV
$8.6B
| $1.16M | 0.45% |
115,326
| – | – |
|
102
Petrobras Class A
PBR.A
$73.4B
| $1.16M | 0.45% |
+89,000
| New | +$1.16M |
|
103
Banco Bradesco
BBD
$31.9B
| $1.15M | 0.44% |
517,000
-215,200
| -29% | -$480K |
|
104
Corporacion America
CAAP
$3.43B
| $1.1M | 0.42% |
+60,200
| New | +$1.1M |
|
105
RBC Bearings
RBC
$12.1B
| $1.09M | 0.42% |
+3,400
| New | +$1.09M |
|
|
VRNA
106
Verona Pharma
VRNA
$9.18B
| $1.06M | 0.41% |
16,701
-7,038
| -30% | -$447K |
|
107
Coupang
CPNG
$51.6B
| $1.04M | 0.4% |
47,500
-22,200
| -32% | -$487K |
|
108
HubSpot
HUBS
$24.9B
| $1.03M | 0.4% |
+1,800
| New | +$1.03M |
|
109
Soleno Therapeutics
SLNO
$3.56B
| $1.02M | 0.39% |
14,344
| – | – |
|
110
Nu Holdings
NU
$72B
| $1.02M | 0.39% |
99,737
-25,324
| -20% | -$259K |
|
111
Scholar Rock
SRRK
$3.3B
| $1M | 0.39% |
+31,230
| New | +$1M |
|
112
Alibaba
BABA
$325B
| $986K | 0.38% |
7,457
-13,400
| -64% | -$1.77M |
|
113
Akero Therapeutics
AKRO
$3.65B
| $974K | 0.38% |
24,067
+11,538
| +92% | +$467K |
|
114
Crinetics Pharmaceuticals
CRNX
$3.26B
| $970K | 0.37% |
28,911
| – | – |
|
115
Ascendis Pharma
ASND
$12.1B
| $946K | 0.36% |
6,072
| – | – |
|
116
Dyne Therapeutics
DYN
$1.92B
| $820K | 0.32% |
78,420
| – | – |
|
117
Olema Pharmaceuticals
OLMA
$432M
| $798K | 0.31% |
212,185
| – | – |
|
118
Trip.com Group
TCOM
$46.6B
| $792K | 0.31% |
12,456
+2,100
| +20% | +$134K |
|
119
Madrigal Pharmaceuticals
MDGL
$9.7B
| $732K | 0.28% |
2,211
| – | – |
|
120
Ocular Therapeutix
OCUL
$2.25B
| $625K | 0.24% |
85,241
| – | – |
|
121
Dianthus Therapeutics
DNTH
$781M
| $569K | 0.22% |
31,387
| – | – |
|
122
Accenture
ACN
$158B
| $562K | 0.22% |
+1,800
| New | +$562K |
|
|
CNTA
123
Centessa Pharmaceuticals
CNTA
$2.13B
| $561K | 0.22% |
39,020
-7,096
| -15% | -$102K |
|
124
CG Oncology
CGON
$2.19B
| $546K | 0.21% |
22,305
| – | – |
|
125
Natera
NTRA
$23B
| $544K | 0.21% |
3,850
-978
| -20% | -$138K |
|